Infinimmune selected KBI Biopharma as its manufacturing partner partly because KBI's Celexis cell line is highly portable. This foresight de-risks future global scale-up, ensuring the manufacturing process can be easily transferred to different facilities worldwide, a key consideration for long-term commercialization and partnerships.

As a cell therapy matures and becomes a later-line treatment, the patient population changes. These patients are more heavily pretreated, and their immune cells are more challenging to grow. This requires continuous process optimization even for an approved product, as the original manufacturing method may no longer be robust enough.

Altering the cell culture media after a master cell bank (MCB) has been created is a high-risk decision. It forces cells to adapt during the seed train of every GMP run, introducing unpredictable, stochastic scenarios where cell behavior can vary from batch to batch, compromising process robustness and consistency.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Many assume genetically modifying Mesenchymal Stem Cells (MSCs) is the main technical hurdle. The greater challenge is developing a robust, reproducible manufacturing process that delivers a functionally equivalent product every time, despite inherent variability from donors and process steps.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

Early CMC decisions for Phase 1 clinical supply are foundational. Certain errors made at this stage, such as failing to prove cell bank clonality, are irreversible and can jeopardize the entire development program, similar to a faulty foundation in a house.

Continuous microbial manufacturing lags behind mammalian systems primarily due to the high replication rate of microbes like E. coli, which causes rapid genetic drift and loss of productivity. The solution is biological, not mechanical: decoupling cell growth from protein production to genetically stabilize the system for long-duration runs.

Resolution Therapeutics' CEO warns that manufacturing process changes cannot wait for pivotal trials in cell therapy. The drug product used in a Phase 1/2 study must be highly comparable to the final commercial version to avoid extremely costly delays and extensive comparability studies later in development.